Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening

Jacqueline Glascock, Jacinda Sampson, Amanda Haidet-Phillips, Anne Connolly, Basil Darras, John Day, Richard Finkel, R. Rodney Howell, Katherine Klinger, Nancy Kuntz, Thomas Prior, Perry B. Shieh, Thomas O. Crawford, Douglas Kerr, Jill Jarecki

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Spinal muscular atrophy (SMA) is an autosomal recessive disease characterized by the degeneration of alpha motor neurons in the spinal cord, leading to muscular atrophy. SMA is caused by deletions or mutations in the survival motor neuron 1 gene (SMN1). In humans, a nearly identical copy gene, SMN2, is present. Because SMN2 has been shown to decrease disease severity in a dose-dependent manner, SMN2 copy number is predictive of disease severity.

OBJECTIVE: To develop a treatment algorithm for SMA-positive infants identified through newborn screening based upon SMN2 copy number.

METHODS: A working group comprised of 15 SMA experts participated in a modified Delphi process, moderated by a neutral third-party expert, to develop treatment guidelines.

RESULTS: The overarching recommendation is that all infants with two or three copies of SMN2 should receive immediate treatment (n = 13). For those infants in which immediate treatment is not recommended, guidelines were developed that outline the timing and appropriate screens and tests to be used to determine the timing of treatment initiation.

CONCLUSIONS: The identification SMA affected infants via newborn screening presents an unprecedented opportunity for achievement of maximal therapeutic benefit through the administration of treatment pre-symptomatically. The recommendations provided here are intended to help formulate treatment guidelines for infants who test positive during the newborn screening process.

Original languageEnglish (US)
Pages (from-to)145-158
Number of pages14
JournalJournal of neuromuscular diseases
Volume5
Issue number2
DOIs
StatePublished - 2018

Keywords

  • Newborn screening
  • SMN1
  • algorithm
  • drug treatment
  • spinal muscular atrophy
  • survival motor neuron (SMN)

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening'. Together they form a unique fingerprint.

  • Cite this

    Glascock, J., Sampson, J., Haidet-Phillips, A., Connolly, A., Darras, B., Day, J., Finkel, R., Howell, R. R., Klinger, K., Kuntz, N., Prior, T., Shieh, P. B., Crawford, T. O., Kerr, D., & Jarecki, J. (2018). Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening. Journal of neuromuscular diseases, 5(2), 145-158. https://doi.org/10.3233/JND-180304